
Chairman's Note



This month's issue of *American Journal of Hematology/Oncology (AJHO)*, a peer-reviewed resource for education and the official journal of Physicians' Education Resource®, LLC, features four peer-reviewed articles on recent advances that could be vital to the future of hematology and oncology treatment.

Our first story focuses on promising prostate cancer research indicating that degarelix may be a viable therapeutic option in the intermittent setting for maintaining PSA suppression, with the therapy found to be a suitable treatment option for men being considered for intermittent androgen ablation.

Metastatic breast cancer is the topic of our next article, which reviews inhibitors for Aurora A kinase signaling. Encouraging trials with alisertib have shown early signals of activity, especially among patients whose tumors are HR+ and HER2-positive.

Next, we look at recent progress in the treatment of transplant-eligible multiple myeloma. While chemotherapy with autologous stem cell transplant has been the mainstay of treatment since the mid-90s, a number of new therapeutic approaches, such as posttransplant consolidation therapy and maintenance therapy, have gained attention as potential treatment strategies.

The American Society of Hematology and the American Society of Clinical Oncology have developed recommendations for "Choosing Wisely," a national initiative to optimize safety and efficiency in healthcare by encouraging evidence-based application of medical investigations and interventions. Our fourth article evaluates these recommendations, highlighting their rationale and anticipated benefits.

This month's CME article is a discussion with George D. Demetri, MD, of the Dana-Farber Cancer Institute in Boston, on the evolving options currently available for managing soft tissue sarcomas.

Thank you for your support of *AJHO* in 2015. We look forward to serving you in the new year. Your comments and suggestions are always welcome, and we also invite you to submit original articles and commentaries.

I hope you have a happy, safe, and enjoyable holiday season!

Michael J. Hennessy, Sr
Chairman and Chief Executive Officer



The content of this publication is for general information purposes only. The reader is encouraged to confirm the information presented with other sources. *American Journal of Hematology/Oncology* makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this publication and expressly disclaims liability for any errors and omissions that may be presented in this publication. *American Journal of Hematology/Oncology* reserves the right to alter or correct any error or omission in the information it provides in this publication, without any obligations. *American Journal of Hematology/Oncology* further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this publication. The views expressed in this publication are those of the authors and do not necessarily reflect the opinion or policy of *American Journal of Hematology/Oncology*.